MX2023003431A - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
MX2023003431A
MX2023003431A MX2023003431A MX2023003431A MX2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A MX 2023003431 A MX2023003431 A MX 2023003431A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
mitapivat
disintegrant
diluent
lubricant
Prior art date
Application number
MX2023003431A
Other languages
English (en)
Spanish (es)
Inventor
Cheuk- Yui LEUNG
Eric Simone
Ophelia Qiping Yin
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2023003431A publication Critical patent/MX2023003431A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023003431A 2020-09-25 2021-09-24 Formulacion farmaceutica. MX2023003431A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063083834P 2020-09-25 2020-09-25
US202063107196P 2020-10-29 2020-10-29
US202163238483P 2021-08-30 2021-08-30
PCT/US2021/051957 WO2022067039A1 (en) 2020-09-25 2021-09-24 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX2023003431A true MX2023003431A (es) 2023-05-12

Family

ID=78179552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003431A MX2023003431A (es) 2020-09-25 2021-09-24 Formulacion farmaceutica.

Country Status (10)

Country Link
US (1) US20230338283A1 (https=)
EP (1) EP4216956A1 (https=)
JP (1) JP2023542701A (https=)
KR (1) KR20230074536A (https=)
AU (1) AU2021347349A1 (https=)
CA (1) CA3196829A1 (https=)
IL (1) IL301596A (https=)
MX (1) MX2023003431A (https=)
TW (1) TW202228691A (https=)
WO (1) WO2022067039A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598337B (zh) 2009-06-29 2017-09-11 阿吉歐斯製藥公司 治療化合物及組成物
CA2989111C (en) 2015-06-11 2023-10-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
KR102777452B1 (ko) 2017-11-22 2025-03-10 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태

Also Published As

Publication number Publication date
US20230338283A1 (en) 2023-10-26
TW202228691A (zh) 2022-08-01
KR20230074536A (ko) 2023-05-30
JP2023542701A (ja) 2023-10-11
EP4216956A1 (en) 2023-08-02
CA3196829A1 (en) 2022-03-31
WO2022067039A1 (en) 2022-03-31
AU2021347349A1 (en) 2023-06-08
IL301596A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
EP4706671A3 (en) Conjugated hepcidin mimetics
EP4410291A3 (en) Erbb receptor inhibitors
ZA201803678B (en) Pharmaceutical composition
WO2020086747A3 (en) Ssao inhibitors and uses thereof
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
SG11201808607SA (en) Medicine obtained by combining fxr agonist and arb
WO2018183089A8 (en) Compositions for treating and/or preventing cancer
MY209101A (en) Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
MY208983A (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
PH12017502322A1 (en) Therapeutic agent for fibrosis
JOP20210061A1 (ar) توصيل مستمر لبولي ببتيدات 3 تشبه أنجيوبويتين
MX2021010115A (es) Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
MX2020013352A (es) Tratamiento para migrañas.
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
JOP20190040A1 (ar) توليفة من ناهضات fxr
MY207759A (en) Pharmaceutical drug containing heterocyclidene acetamide derivative
MX2021013488A (es) Formulaciones liquidas de dosis oral de metilnaltrexona.
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
MX2023003431A (es) Formulacion farmaceutica.
MX2021005681A (es) Combinacion de un inhibidor de mcl-1 y midostaurina, usos y composiciones farmaceuticas de la misma.
CR20230526A (es) Formulación de sotorasib
MX2018003456A (es) Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor.
WO2020247565A8 (en) Oral care composition
BR112018003392A2 (pt) composição farmacêutica compreendendo um inibidor da hmg-coa redutase e um inibidor eca